Handelsavisen
prelaunch
Companies Healthcare LDDD.PK
LD
LDDD.PK OTC Healthcare Providers & Services

Lddd.Pk

$0,51
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
13,0 %
ROE
38,9 %
Net margin
10,8 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-08-09
Ex-dividend
TR 1Y
About

LDDD.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

Business. LDDD.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

Classification99 %
SectorHealth Care
Industry groupHealthcare Providers & Services
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
38,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning LDDD.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to LDDD.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    LDDD.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

    Classification99 %
    SectorHealth Care
    Industry groupHealthcare Providers & Services
    AI synthesis
    GENERATED

    LDDD.PK maintains a strong liquidity position, with a current ratio of 2.18, indicating the company can easily cover its short-term liabilities with its current assets. The company has no long-term debt and holds significant cash and equivalents of $1.64 million, which supports its liquidity and financial flexibility. The free cash flow of $570,170 further reinforces its ability to fund operations and potentially invest in growth opportunities.

    In terms of profitability, LDDD.PK demonstrates a return on equity (ROE) of 38.87% and a return on assets (ROA) of 21.65%, both of which are strong indicators of efficient capital use and asset management. These metrics suggest the company is generating substantial returns relative to its equity and total assets, outperforming many industry peers in terms of profitability.

    The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher operational and market risks if its primary business line or region experiences a downturn.

    Looking ahead, LDDD.PK is positioned for continued growth, with a strong operating cash flow of $277,370 and a net income of $460,440. While specific growth projections for the next fiscal year are not provided, the company's financial health and profitability suggest a positive trajectory. The absence of dilution risk and the low liquidity risk further support a stable growth outlook.

    The risk assessment for LDDD.PK indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is robust, with no long-term debt and a high proportion of equity, reducing the likelihood of financial distress. The absence of dilution risk is also a positive factor, as it suggests the company is not likely to issue additional shares in the near term, preserving shareholder value.

    Recent filings and transcripts do not indicate any material events or strategic shifts that would significantly impact the company's operations or financial performance. The company appears to be maintaining a stable and profitable business model without major disruptions.

    Key takeaways
    • LDDD.PK has a strong liquidity position with a current ratio of 2.18 and no long-term debt.
    • The company generates high returns on equity (38.87%) and assets (21.65%), indicating efficient capital use.
    • Revenue is concentrated in a single business segment, which may increase operational risk.
    • The company is positioned for continued growth with strong operating cash flow and net income.
    • Low liquidity and dilution risk support a stable financial outlook.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,51
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.2M
    Net cash
    $1.6M
    Current ratio
    2.2
    Debt / equity
    0.0
    ROA
    21.6%
    ROE
    38.9%
    Cash conversion
    60.0%
    CapEx / revenue
    -1.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryHealthcare Providers & Services16,0B node revenueOPCH 35,3%PACS 33,0%PRVA 13,3%SHC 7,3%NUTX 5,5%TOI 3,1%VMD 1,7%JYNT 0,3%Other 0,5%
    Source: company disclosures · own-taxonomy revenue-covered setLDDD 0,0% · rank #14 of 16

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs LDDD · multiples and returns
    OP
    OPCH
    Option Care Health Inc
    $22,09
    3,5B USD
    P/E
    16,5x
    vs self
    Div yield
    vs self
    ROE
    15,5 %
    vs self
    PA
    PACS
    Pacs Group Inc
    $38,00
    6,0B USD
    P/E
    25,2x
    vs self
    Div yield
    vs self
    ROE
    25,8 %
    vs self
    PR
    PRVA
    Privia Health Group Inc
    $23,90
    3,0B USD
    P/E
    123,6x
    vs self
    Div yield
    vs self
    ROE
    3,1 %
    vs self
    SH
    SHC
    Sotera Health Co
    $18,00
    5,1B USD
    P/E
    57,5x
    vs self
    Div yield
    vs self
    ROE
    12,9 %
    vs self
    NU
    NUTX
    NUTEX HEALTH INC.
    $176,00
    1,2B USD
    P/E
    9,7x
    vs self
    Div yield
    vs self
    ROE
    29,2 %
    vs self
    TO
    TOI
    Oncology Institute Inc
    $5,18
    527,8M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    372,2 %
    vs self
    VM
    VMD
    Viemed Healthcare Inc
    $11,00
    445,4M USD
    P/E
    26,7x
    vs self
    Div yield
    vs self
    ROE
    10,4 %
    vs self
    JY
    JYNT
    Joint Corp
    $8,21
    117,0M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -15,5 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin13,0 %Above median
    Net Margin10,8 %Above P75
    ROE38,9 %Above P75
    Capex / Rev-1,4 %Below median
    D/E0,00Above median
    Cash Conv0,60Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • LDDD.PK Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    4shares short0.0% vs prior
    999.99days to cover
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    LDDD.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Current ratio (FY 2025-12-31): 1.57xDerived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -19.3%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.30xDerived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 15.5%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -4.4%Derived (calculated)
    • Shares outstanding (annual): 30.02MSEC XBRL filing
    • Total liabilities (annual): USD 1.14MSEC XBRL filing
    • Current assets (annual): USD 1.76MSEC XBRL filing
    • Shareholders' equity (annual): USD 880.36KSEC XBRL filing
    • Current liabilities (annual): USD 1.12MSEC XBRL filing
    • Total assets (annual): USD 2.1MSEC XBRL filing
    • Gross profit (YoY) (2025-06-30 vs 2024-06-30): -42.2%Derived (calculated)
    • Operating income (YoY) (2025-06-30 vs 2024-06-30): -72.7%Derived (calculated)
    • Net income (YoY) (2025-06-30 vs 2024-06-30): -63.3%Derived (calculated)
    • Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): -52.4%Derived (calculated)
    • Net margin (FY 2025-06-30): 10.8%Derived (calculated)
    • Gross margin (FY 2025-06-30): 97.9%Derived (calculated)
    • Capex (YoY) (2025-06-30 vs 2024-06-30): -80.6%Derived (calculated)
    • Cost of revenue (YoY) (2025-06-30 vs 2024-06-30): -47.4%Derived (calculated)
    • EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): -64.3%Derived (calculated)
    • Revenue (YoY) (2025-06-30 vs 2024-06-30): -42.3%Derived (calculated)
    • EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): -64.3%Derived (calculated)
    • Operating income (annual): USD 552.68KSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage